The short answer: what makes someone suitable

ChondroFiller injection is suited to adults with full-thickness articular cartilage damage — predominantly ICRS or Outerbridge grade III or IV — where the joint is otherwise structurally sound enough to support a regenerative response.

Two broad patient groups fit this pathway. The first comprises people with a focal, contained chondral defect: a discrete area of damage with intact cartilage at its margins, most commonly caused by trauma, osteochondritis dissecans (OCD), or cartilage loss that has developed after a meniscal injury or ligament reconstruction. The second group includes those with more diffuse joint degeneration, where the injectable collagen scaffold is placed to coat the articular surface and support the body's own repair through acellular matrix-induced chondrogenesis — recruiting the patient's progenitor cells rather than replacing lost tissue with a synthetic filler.

Age alone does not disqualify anyone; the injection pathway carries no formal upper age limit. In practice, active patients aged 40–65 who maintain a healthy weight tend to achieve the best regenerative outcomes, reflecting the capacity for host-cell migration at that stage. Younger patients with trauma-related damage are the classical presentation, but older patients with symptomatic wear are not excluded.

None of this, however, amounts to a self-checklist. An MRI is always the mandatory starting point — it confirms whether damage is focal or diffuse, measures defect geometry, and identifies features that would redirect care to a different pathway entirely.

Defect size — why ChondroFiller works differently from surgery

Most conventional cartilage repair techniques operate within strict size thresholds. Microfracture and mosaicplasty are generally suited to lesions below 2–4 cm² — roughly the surface area of a thumbnail — while MACI (matrix-induced autologous chondrocyte implantation) becomes the preferred surgical choice for defects at or above 3 cm². These limits exist because each technique must bridge or fill a precisely defined defect boundary; size is the primary sorting gate.

The injectable collagen scaffold works on a different principle. Rather than filling a discrete gap, ChondroFiller coats the articular surface across the joint compartment, removing the need for a binary size cut-off. The regenerative sweet spot for the ultrasound-guided injection pathway is up to 4 cm², where host-cell recruitment and scaffold integration tend to be most predictable. Contained defects between 4 and 6 cm² can also be treated via the injection route — clinic sources confirm no formal upper defect-size limit applies to the in-clinic injection pathway.

Once a defect approaches or exceeds 6 cm², or where the clinical picture calls for biological adjuncts, the Liquid Cartilage™ pathway may be the more appropriate option. This is an entirely separate surgical procedure — not a variation of the in-clinic injection — in which ChondroFiller is used alongside biological adjuncts in a different setting. Which route is recommended depends on defect geometry, containment, and the wider joint picture, and is determined through imaging and specialist review rather than by any single size threshold.

Joint alignment and mechanical stability

Even the most suitable cartilage defect will not respond well to a regenerative scaffold if the joint around it is mechanically unsound. Uneven load distribution — caused by ligament laxity, malalignment, or abnormal patellar tracking — applies stress across the repair site that can prevent the collagen matrix from integrating properly and undermine longer-term outcomes.

The criteria are straightforward. Ligaments must be sufficiently stable: significant laxity that alters joint kinematics would need to be addressed before or alongside treatment. Where the patellofemoral compartment is involved, normal patellar tracking is expected, since lateral maltracking concentrates pressure unevenly across the trochlear surface. Axial alignment should fall within approximately 5° of neutral — pronounced varus (bow-legged) or valgus (knock-kneed) deformity shifts load into the compartment being treated, and correction may be recommended first.

None of these findings represents an automatic disqualifier. In practice, they become factors within the specialist's overall joint assessment, and correction of an alignment problem or instability may be planned as a co-treatment rather than a reason to close the door on the injection pathway entirely.

Advanced OA and 'bone on bone' — not an automatic exclusion

Many patients arrive having been told by a GP or previous specialist that they are 'too far gone' for regenerative treatment. A plain X-ray showing Kellgren-Lawrence Grade III or IV changes — sometimes described as 'bone on bone' — does not automatically close the door on the ChondroFiller injection pathway.

What changes is the assessment track. Where a focal, well-contained defect routes through the standard criteria outlined above, more widespread or advanced joint degeneration is evaluated on a separate diffuse OA pathway. The X-ray finding is a prompt to look more carefully — via MRI — not a rejection letter.

For patients assessed as suitable on that diffuse track, ChondroFiller injection may be combined with Arthrosamid, a polyacrylamide hydrogel licensed for knee OA. These are distinct products working through entirely different mechanisms: ChondroFiller is the regenerative scaffold component; Arthrosamid is a non-regenerative hydrogel that addresses joint-space support through a cushioning effect. The two are not interchangeable, and Arthrosamid is not being recommended here as a stand-alone therapy — its role in this context is as a combination adjunct where the clinical picture warrants it.

The most advanced cases — where joint preservation would otherwise seem impossible — may be considered for a tri-active protocol that adds autologous mesenchymal stem cells to the dual injection. This is not a default pathway. Each of these combined protocols requires careful specialist assessment, and the decision rests on MRI findings, symptom profile, and the clinician's overall evaluation of the joint.

When ChondroFiller injection is not suitable

Three conditions represent hard stops for the ChondroFiller injection pathway — not clinical judgement calls, and not factors that a different dosage or combination protocol can overcome.

Diffuse OA with uncontained lesions. Where cartilage damage is so extensive that the defect edges are no longer surrounded by intact cartilage, the scaffold has no structural border to support integration. This is distinct from the diffuse OA track described above, where some degree of containment remains.

Inflammatory arthritis. Active joint inflammation — rheumatoid arthritis being the principal example — creates a biochemical environment that prevents the collagen matrix from recruiting and retaining the host cells needed for repair.

Allergy to collagen or murine-derived protein. ChondroFiller is composed of type I collagen derived from murine sources; an allergy to either component is an absolute contraindication.

Patients who fall into any of these categories are not without options, but those pathways — whether disease-modifying therapy, alternative joint-preservation strategies, or surgical planning — are a matter for specialist consultation.

How suitability is assessed — MRI, the AMSK framework, and next steps

No online symptom checklist can substitute for what a single MRI scan reveals. The scan differentiates focal from diffuse damage, measures defect geometry, and identifies subchondral bone changes that would redirect a patient toward a different pathway entirely — these are the variables on which the criteria described in earlier sections actually turn.

That imaging review sits within a broader structured assessment. The AMSK framework evaluates candidacy across four dimensions: joint mechanics, the biological joint environment, tissue condition, and the timing of wear progression. Rather than producing a binary verdict, this routes each patient to one of four care pathways — because two patients with identical lesion sizes on MRI may have very different overall joint profiles.

ChondroFiller injection is also typically considered after a fair trial of conservative management. Physiotherapy and activity modification come first; the injection pathway is generally offered when those measures have not delivered adequate relief.

For patients who do proceed, the published evidence provides a useful reference point. Clinical data suggest IKDC scores improve by approximately 30 points; across published series, 70–85% of patients achieve meaningful symptom relief at three to five years. Complication rates are reported at approximately 0%, with reoperation rates of 3–8% — considerably lower than those associated with microfracture (up to 41%) or ACI/MACI (up to 37%). ChondroFiller holds Class III CE-mark status and is accessed privately in the UK; it is not NHS-funded.

The clearest signal that a patient is well placed for this pathway is a focal, contained defect in a mechanically stable joint, confirmed on MRI after conservative treatment has been tried. The clearest counter-signal is inflammatory joint disease, an uncontained lesion, or a collagen allergy. For presentations that fall between those poles — which is to say, most presentations — a specialist imaging-led assessment determines the route. That conversation can begin at londoncartilage.com, where Professor Paul Y. F. Lee leads candidacy review for the ChondroFiller injection pathway.